Compare Summit Therapeutics Inc (SMMT) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Materials Select Sector SPDR Fund — how do they compare? Summit Therapeutics Inc trades at $17.58 (market cap $13.98B), while Materials Select Sector SPDR Fund trades at $51.45. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | XLB | |
|---|---|---|
Market Cap | $13.98B | — |
Sector | Health | — |
52-Week High | $26.38 | $53.67 |
52-Week Low | $12.43 | $42.23 |
Enterprise Value | $13.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
XLB trades at $51.95, down 0.93% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The materials sector ETF benefits from AI infrastructure trends and strong Q2 earnings momentum across the sector. Recent news highlights potential opportunities in materials as investors rotate toward tangible assets.
The outlook for XLB appears constructive given sector tailwinds from infrastructure spending and AI buildout, though cyclical recovery may be partially priced in. Key risks include materials price volatility and geopolitical supply chain pressures. Analyst sentiment is mixed with some viewing current levels as fully valued after recent sector rebound.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
